The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels

Abstract Background Testosterone suppression is the standard treatment for advanced prostate cancer, and it is associated with side-effects that impair patients’ quality of life, like sexual dysfunction, osteoporosis, weight gain, and increased cardiovascular risk. We hypothesized that abiraterone a...

Full description

Bibliographic Details
Main Authors: Gustavo Werutsky, Fernando Cotait Maluf, Eduardo Henrique Cronemberger, Vinicius Carrera Souza, Suelen Patricia dos Santos Martins, Fábio Peixoto, Oren Smaletz, Fábio Schutz, Daniel Herchenhorn, Telma Santos, Flavio Mavignier Carcano, David Queiroz Muniz, Paulo R. S. Nunes Filho, Facundo Zaffaroni, Carlos Barrios, André Fay
Format: Article
Language:English
Published: BMC 2019-05-01
Series:BMC Cancer
Subjects:
Castration-sensitive prostate cancer
Hormonal therapy
Androgen deprivation therapy
Abiraterone
Apalutamide
Goserelin
Online Access:http://link.springer.com/article/10.1186/s12885-019-5709-y

Internet

http://link.springer.com/article/10.1186/s12885-019-5709-y

Similar Items